New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 18, 2014
14:22 EDTQDELQuidel granted Emergency Use Authorization from FDA for H7N9 flu test
The FDA granted Quidel's request to authorize the emergency use of the Lyra Influenza A Subtype H7N9 Assay on certain instruments for the presumptive detection of influenza A, H7N9, virus, which was detected in China in 2013, according to a letter, dated Feb. 14, posted to the FDA's website. Reference Link
News For QDEL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
07:39 EDTQDELQuidel price target raised to $30 from $27 at Canaccord
Subscribe for More Information
05:44 EDTQDELQuidel price target raised to $31 from $27 at Piper Jaffray
Subscribe for More Information
October 21, 2014
16:19 EDTQDELQuidel reports Q3 EPS (1c), consensus (12c)
Subscribe for More Information
October 15, 2014
14:01 EDTQDELQuidel receives FDA clearance for Lyra molecular PCR assay
Subscribe for More Information
October 13, 2014
14:01 EDTQDELQuidel receives FDA clearance for Lyra molecular PCR assay
Quidel announced that it has received 510k clearance from the FDA to market its Lyra Adenovirus Assay, a real-time PCR test for the qualitative detection of human adenovirus viral DNA isolated from nasal swab and nasopharyngeal swab specimens. Adenovirus outbreaks can occur throughout the year, but are more common from late winter to early summer. Quidel's Lyra Adenovirus Assay is part of the new Lyra brand of ready-to-use, molecular PCR reagent kits specifically designed to be compatible with a laboratory's existing thermocycler.
10:59 EDTQDELEbola in U.S. could boost flu testing, says Piper Jaffray
Piper Jaffray believes the emergence of Ebola cases in the U.S. could drive incremental flu testing since the disease shares some initial symptoms with flu, likely driving people to get a test. Piper says it has increased confidence in its flu upside scenario for Quidel. It has an Overweight rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use